ACC 2023 Highlights Podcast

In this episode, Medicom’s correspondent covers 6 presentations from the annual meeting of the American College of Cardiology (ACC 2023), held in New Orleans, LA, USA, from 4-6 March 2023.

The topics discussed are:

1. Bempedoic acid in statin-intolerant patients at high cardiovascular risk
   Among statin-intolerant patients, treatment with bempedoic acid lowered low-density lipoprotein cholesterol (LDL-C) and effectively reduced the risk of major adverse cardiovascular events. This was established in the phase 3, double-blind, randomised, placebo-controlled CLEAR Outcomes trial.
2. Inflammation stronger predictor of MACE than cholesterol levels
   A collaborative analysis of the PROMINENT, REDUCE-IT, and STRENGTH trials showed that residual inflammatory risk is a better predictor of future major adverse cardiovascular events, cardiovascular death, and all-cause mortality than residual cholesterol risk in statin-treated patients. Thus, targeting low-density lipoprotein cholesterol alone is unlikely to completely reduce atherosclerotic risk.
3. Transcatheter repair for patients with tricuspid regurgitationTricuspid transcatheter edge-to-edge repair reduced the severity of tricuspid regurgitation at 1 year and was associated with an improved quality of life in patients with severe tricuspid regurgitation. These were the main findings of the prospective, randomised TRILUMINATE trial.
4. RENOVATE-COMPLEX-PCI results support intravascular-guided PCI for complex lesionsThe RENOVATE-COMPLEX-PCI trial showed that percutaneous coronary intervention (PCI) guided by intravascular imaging for complex coronary artery lesions was associated with a lower risk of death than angiography-guided PCI.
5. Minimally invasive versus conventional sternotomy for mitral valve repair
   The best surgical approach for mitral valve repair is subject to wide debate. Findings from the randomised UK Mini Mitral trial showed similar improvement in physical activity, surgical outcomes and quality of life in patients undergoing minimally invasive and conventional surgical techniques for mitral valve repair.
6. Sotatercept improves exercise capacity in patients with PAHSotatercept is a fusion protein that traps activins and growth differentiation factors involved in pulmonary arterial hypertension (PAH). Adding this novel first-in-class agent to background PAH therapy led to significant and clinically relevant improvements in exercise capacity and other endpoints in the placebo-controlled STELLAR trial.

Enjoy listening!

Copyright ©2023 Medicom Medical Publishers



Posted on 22 March 202327 June 2024